Amerant (AMTB) Q1 2026 Earnings Call Transcript

Amerant Bancorp reported Q1 diluted EPS of $0.44 versus $0.07 in Q4, helped by a 37.3% sequential drop in noninterest expense to $66.9 million and a jump in PPNR to $30.7 million. Net interest income fell to $80.3 million and NIM compressed to 3.55%, but deposits grew $152.2 million to $7.9 billion, aided by $95 million from Venezuela, while CET1 remained strong at 11.84%. Management guided to $68 million-$69 million of quarterly expenses in Q2, ~7% annualized loan growth, and 8%-10% deposit growth for 2026, while continuing buybacks with $21 million still authorized.

Analysis

The key signal is not the headline earnings rebound, but the company’s shift from balance-sheet beta to operational cleanup. The market is likely to over-penalize the lower NII bridge and underappreciate that management is deliberately shrinking the probability distribution of future credit outcomes; that should compress volatility in reported earnings over the next 2-3 quarters. If the derisking exits complete as planned, the earnings stream should become more levered to fee income, buybacks, and low-cost funding rather than reserve releases.

The Venezuelan deposit story is the real second-order driver. Those balances are described as sub-1% marginal funding, which means every incremental dollar there has a disproportionate impact on NIM versus a conventional domestic deposit dollar; that can partially offset loan yield compression even if asset pricing stays under pressure. The hidden risk is policy/reputational rather than purely financial: a deterioration in sanctions optics or local transferability could quickly turn this into a funding overhang, especially if competitors start bidding for the same flows and compress the spread advantage.

Credit metrics are still noisy, but the more important tell is management’s willingness to continue selling and reclassifying assets even when it hits near-term revenue. That usually precedes a cleaner multiple, not a faster top line, because it removes the market’s fear of surprise charge-offs and allows the buyback to matter more. The current setup looks like a “show me” story for 1H26 with potential multiple expansion if NPLs and special mentions keep rolling down while expenses hold near the newly established run-rate.

Contrarian view: consensus may be too focused on the sequential NII decline and too skeptical of the low-cost funding opportunity. If the company can sustain ~$68M quarterly expenses and keep capital above 11.5% CET1 while repurchasing stock near or below tangible book, the equity can rerate even without strong loan growth. The main failure mode is that de-risking becomes perpetual, funding quality deteriorates, or the Venezuela thesis proves episodic rather than structural.

Key Decisions for Investors

• Long AMTB into the next 1-2 quarters on a watchlist basis; thesis is expense durability plus de-risking-driven multiple expansion. Risk/reward improves if the stock remains near tangible book and management keeps executing buybacks.
• Sell downside via AMTB cash-secured puts or a put spread expiring after the next two earnings prints; the setup favors mean reversion if credit metrics stabilize, while capping premium outlay if the Venezuela funding story stumbles.
• Pair trade: long AMTB vs short a slower-cleanup regional bank with weaker capital return discipline; the trade expresses relative improvement in credit visibility and buyback support rather than outright rate beta.
• If AMTB rallies materially above tangible book before the next quarter, trim exposure and wait for confirmation on NIM stabilization; the near-term upside is more likely to come from multiple re-rate than from fundamental acceleration.
• Monitor for a catalyst-driven add on confirmation that special mentions fall below the next exit target and quarterly expense run-rate holds near $68M; that would validate the thesis that earnings power is resetting higher even with modest loan growth.